Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Gianotti N, et al. Among authors: pinnetti c. J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. J Antimicrob Chemother. 2019. PMID: 31173639
HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
Tamburrini E, Ravizza M, Floridia M, Tibaldi C, Alberico S, Anzidei G, Maccabruni A, Meloni A, Antoni AD, Mori F, Dalzero S, Conservan V, Pinnetti C, Ferrazzi E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Tamburrini E, et al. Among authors: pinnetti c. Antivir Ther. 2008;13(4):519-27. Antivir Ther. 2008. PMID: 18672530
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, Cauda R, Anzidei G, Cusato M, Regazzi M, Floridia M, Tamburrini E. Pinnetti C, et al. J Antimicrob Chemother. 2010 Sep;65(9):2050-2. doi: 10.1093/jac/dkq264. Epub 2010 Jul 14. J Antimicrob Chemother. 2010. PMID: 20630894 No abstract available.
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy.
Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, Di Giacomo C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. Bibas M, et al. Among authors: pinnetti c. Am J Hematol. 2012 Aug;87(8):749-53. doi: 10.1002/ajh.23236. Epub 2012 Jun 20. Am J Hematol. 2012. PMID: 22718364 Free article. Clinical Trial.
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Santoro MM, et al. Among authors: pinnetti c. Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23343501 Free article.
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort. d'Arminio Monforte A, et al. Among authors: pinnetti c. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13. Antivir Ther. 2014. PMID: 24036891
160 results